Sis B, Famulski K S, Allanach K L, Zhu L-F, Halloran P F
Department of Medicine, Division of Nephrology & Transplantation Immunology, University of Alberta, Edmonton, Alberta, Canada.
Am J Transplant. 2007 Oct;7(10):2301-10. doi: 10.1111/j.1600-6143.2007.01947.x.
Interferon-gamma (Ifng) protects organ allografts: mouse kidney allografts lacking Ifng receptors rapidly fail with massive ischemic necrosis around days 5 to 7, reflecting microcirculation failure. We hypothesized that Ifng protects the graft by preventing perforin-granzyme-mediated cytotoxic damage to the microcirculation by inducing class Ia and/or Ib products. We transplanted kidney allografts lacking Ifng receptors into various knockout hosts. The necrosis/congestion phenotype did not require host B cells or IL-4 and IL-13 receptors, but required the T-cell alloresponse: it did not occur if the hosts were syngeneic or T-cell deficient. However, host perforin-granzyme mechanisms were required: no necrosis developed if hosts lacked either perforin or granzymes A and B. The ability of Ifng to protect the allograft required donor class I products: allografts lacking class I products due to Tap1 or beta2 microglobulin deficiency developed a similar necrosis-congestion phenotype at day 7 despite Ifng receptors being present. Thus when host cytotoxic T cells infiltrate organ allografts, Ifng prevents their perforin-granzyme mechanism from compromising the microcirculation by a mechanism requiring donor class Ia or Ib products. We propose that donor class Ia or Ib products are needed to trigger inhibitory receptors on effector T cells.
干扰素-γ(Ifng)可保护器官移植:缺乏Ifng受体的小鼠肾移植在第5至7天左右会迅速失败,伴有大量缺血性坏死,这反映了微循环衰竭。我们推测Ifng通过诱导I类a和/或I类b产物来防止穿孔素-颗粒酶介导的对微循环的细胞毒性损伤,从而保护移植器官。我们将缺乏Ifng受体的肾移植到各种基因敲除宿主中。坏死/充血表型不需要宿主B细胞或IL-4和IL-13受体,但需要T细胞同种异体反应:如果宿主是同基因的或T细胞缺陷的,则不会出现这种情况。然而,宿主的穿孔素-颗粒酶机制是必需的:如果宿主缺乏穿孔素或颗粒酶A和B,则不会发生坏死。Ifng保护移植器官的能力需要供体I类产物:由于Tap1或β2微球蛋白缺陷而缺乏I类产物的移植器官,尽管存在Ifng受体,在第7天仍会出现类似的坏死-充血表型。因此,当宿主细胞毒性T细胞浸润器官移植时,Ifng通过一种需要供体I类a或I类b产物的机制,防止其穿孔素-颗粒酶机制损害微循环。我们提出,需要供体I类a或I类b产物来触发效应T细胞上的抑制性受体。